作者：
MacLachlan, Timothy K. [1]
;
Price, Shari [2]
;
Cavagnaro, Joy [3]
;
Andrews, Laura [4]
;
Blanset, Diann [5]
;
Cosenza, Mary Ellen [6]
;
Dempster, Maggie [7]
;
Galbreath, Elizabeth [8]
;
Giusti, Anna Maria [9]
;
Heinz-Taheny, Kathleen Marie [10]
;
Fleurance, Renaud [11]
;
Sutter, Esther [12]
;
Leach, Michael W. [13]
作者单位：
Novartis Inst Biomed Res, Basel, Switzerland
[1]
MEC Regulatory & Toxicol Consulting LLC, Moorpark, CA 93021 USA
[2]
GlaxoSmithKline, 1250 South Collegeville Rd, Collegeville, PA 19426 USA
[3]
Novartis Inst Biomed Res, Cambridge, MA 01239 USA
[4]
Takeda US Inc, Drug Safety Res & Evaluat, Cambridge, MA USA
[5]
UCB BioPharma SRL, B-1420 Braine Lalleud, Belgium
[6]
AbbVie, 100 Res Dr, Worcester, MA 01520 USA
[7]
Access BIO LC, Boyce, VA 22620 USA
[8]
Charles River Labs, 15 Wormans Mill Court,Suite 1, Frederick, MD 21701 USA
[9]
Pfizer Inc, Drug Safety Res & Dev, 300 Technol Sq, Cambridge, MA 02139 USA
[10]
Roche Innovat Ctr Zurich, Pharmaceut Sci, Roche Pharma Res & Early Dev, Zurich, Switzerland
[11]
Eli Lilly & Co, Lilly Corp Ctr, Toxicol & Pathol, Indianapolis, IN 46285 USA
[12]
Boehringer Ingelheim GmbH & Co KG, 900 Ridgebury Rd, Ridgefield, CT 06877 USA
[13]
发布时间
2021-08-19
换一批
换一批
